| DD said: |
Conventional hematotoxicity testing involves measuring different mature blood-cell components, over time after administation of an agent. For proliferating systems, major toxicity does not occur in mature cells but in the cells responsible for producing the mature cells, namely the stem and progenitor cells for the lymphohematopoeitic system.
For stem cell hemotoxicity to play a role at all stages of drug development, the HALO ( Hematopoeitic/hematotoxicity Assays via Luminescence Output), was developed. Does anyone know the name of company/ies that provide Halo platforms? |
HALO exactly stands for Hematopoietic/Hemocytotoxicity
Assay via
Luminescence Output. HALO Tag fusion
proteins are used in different sub-cellular locations: Nucleus,
Mitochondria, Cytosol, etc.
Cells can be labeled with
fluorescence HaloTag
ligand and images observed by
fluorescent microscopes. The HaloTag technology is available by
Promegawww.promega.com and is a new method of
labeling target
proteins within the
cell that can be used in functional
assays. It allows observing
cells over long period of time so studies such as
drug exposures can be done.